Change in Pgp Expression and Function in Pgp-Positive Blasts
| Drug Treatment . | Pgp Upregulation*/ No. Tested . | Ratio of Pgp MCF† . | Increase in Pgp Function‡/No. Tested . | Ratio of Rh123 MCF† . | ||
|---|---|---|---|---|---|---|
| Range . | Mean ± SE . | Range . | Mean ± SE . | |||
| Control | 0/9 | 1.17-2.22 | 1.44 ± 0.09 | 0/5 | 1.06-1.15 | 1.10 ± 0.02 |
| IDA | 4/7 | 1.31-1.96 | 1.69 ± 0.09 | 1/3 | 1.11-1.37 | 1.22 ± 0.08 |
| MX2 | 8/9 | 1.30-2.53 | 1.87 ± 0.142-153 | 5/5 | 1.15-1.68 | 1.31 ± 0.092-153 |
| EPI | 7/8 | 1.20-2.19 | 1.67 ± 0.10 | 2/3 | 1.15-1.44 | 1.26 ± 0.09 |
| DAU | 4/5 | 1.33-2.24 | 1.81 ± 0.112-153 | 3/3 | 1.28-1.49 | 1.35 ± 0.052-153 |
| AraC | 4/5 | 1.39-2.31 | 1.79 ± 0.132-153 | 3/3 | 1.25-1.41 | 1.31 ± 0.032-153 |
| Drug Treatment . | Pgp Upregulation*/ No. Tested . | Ratio of Pgp MCF† . | Increase in Pgp Function‡/No. Tested . | Ratio of Rh123 MCF† . | ||
|---|---|---|---|---|---|---|
| Range . | Mean ± SE . | Range . | Mean ± SE . | |||
| Control | 0/9 | 1.17-2.22 | 1.44 ± 0.09 | 0/5 | 1.06-1.15 | 1.10 ± 0.02 |
| IDA | 4/7 | 1.31-1.96 | 1.69 ± 0.09 | 1/3 | 1.11-1.37 | 1.22 ± 0.08 |
| MX2 | 8/9 | 1.30-2.53 | 1.87 ± 0.142-153 | 5/5 | 1.15-1.68 | 1.31 ± 0.092-153 |
| EPI | 7/8 | 1.20-2.19 | 1.67 ± 0.10 | 2/3 | 1.15-1.44 | 1.26 ± 0.09 |
| DAU | 4/5 | 1.33-2.24 | 1.81 ± 0.112-153 | 3/3 | 1.28-1.49 | 1.35 ± 0.052-153 |
| AraC | 4/5 | 1.39-2.31 | 1.79 ± 0.132-153 | 3/3 | 1.25-1.41 | 1.31 ± 0.032-153 |
Pgp induction (upregulation) was defined as a change in Pgp ratio of treated compared with untreated blasts of ≥10% as described in Materials and Methods.
Pgp expression or function were expressed as the ratios of the arithmetic mean of fluorescence (MCF) of MRK 16 versus the IgG2a control or Rh123 fluorescence in the presence or absence of 2 μmol/L PSC 833 (mean ± SE) from 9 samples that were Pgp-negative before treatment. Statistical analysis was performed by analysis of variance as described in Materials and Methods.
An increase in Pgp function was defined as a change in the Rh123 ratio (MCF of Rh123 in the presence or absence of 2 μmol/L PSC 833) of treated compared with untreated blasts of ≥10% as described in Materials and Methods.
P < .05.